Virtual Library
Start Your Search
Jacky Crequit
Author of
-
+
P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 964)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.15-29 - Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01) (ID 11338)
16:45 - 18:00 | Author(s): Jacky Crequit
- Abstract
Background
Antiangiogenic treatments are today restricted to non-squamous NSCLC. New drugs, like ramucirumab, have been approved in second line setting for advanced NSCLC regardless histology but there is little information about the rate of squamous NSLC eligible to these treatments. This descriptive, prospective, observational study aimed to assess the rate of squamous advanced NSCLC patients eligible to anti-angiogenic treatments.
a9ded1e5ce5d75814730bb4caaf49419 Method
Each participating center had to include consecutive relapsed advanced SQ-NSCLC and to assess the presence of common criteria which restricted the use of antiangiogenic treatments (hemoptysis, cardiovascular diseases, tumoral extension to blood vessels and tumoral cavitation).
4c3880bb027f159e801041b1021e88e8 Result
From july 2016 to july 2017, 317 patients were included: 256 (80.8%) men, PS0/1/2 in 30.5%/54.5%/14.9% patients, stage IV in 74.5% of cases. Ineligibility criteria for anti-angiogenic therapy were found in 53.6% of patients (one single criteria in 29,3%, two criteria in 19,9%, three in 3.5%). The main reasons for ineligibility was as followed: blood vessel extension 39.8%, cavitation 20.5%, hemoptysis 7.2%, cardiovascular diseases 12.1%.
Table described patients characteristics according to the ineligibility criteria: Cavitation had the highest number of metastatic disease, cardiovascular diseases the highest number of men and number of metastatic site.
In a non-selected advanced SQ-NSCLC population, only half of these patients are ineligible to a second line anti-angiogenic treatments with a wide majority of tumoral blood vessel extensions and cavitations.
_______________________________________________________________________________________________________________
In collaboration with the GFPC* team and supported by an academic grant from Lilly pharmaceuticals.
*GFPC: French Lung Cancer Group